March 15, 2013 |
Experimental drug treatments promising to slow or reverse the progression of Alzheimer's disease will need to be assessed with a new and more subtle set of rules, a pair of FDA officials wrote this week. The resulting new guidelines, predict some researchers, should allow Alzheimer's drugs under development to travel a faster path to the U.S. market -- and to the more than 5 million Americans who need them. The new guidelines, issued to drug developers last month and outlined this week in the New England Journal of Medicine, reflect a growing shift among both physicians and researchers toward earlier detection and treatment of the memory-robbing disease.
March 15, 2013 |
For seniors and their families, Alzheimer's disease and its hefty price tag are an increasingly scary prospect. About 5.4 million Americans are affected by Alzheimer's disease, making it the sixth leading cause of death in the United States. Because of growing life expectancies and aging baby boomers, that number is expected to triple by 2050. Alayna Tillman's mother and aunt both have Alzheimer's disease and live with Tillman, her husband and two sons in Lake View Terrace. Tillman says Medicare pays for many of the medical costs her mom and aunt incur.
March 11, 2013 |
In patients with moderate Alzheimer's disease, an experimental drug that alters the brain's "fight or flight" impulse succeeded in improving memory modestly when it was added to at least one of the medications already in wide use to treat the memory-robbing disease. Compared with subjects taking the drug memantine and a placebo, subjects supplementing their customary drug regimen for three months with the experimental drug--ORM-12741--scored more highly on two measures of memory.
February 6, 2013 |
As baby boomers enter their golden years, the number of people afflicted with Alzheimer's disease is expected to reach 13.8 million by 2050 - millions more than previously anticipated, according to a new study in the journal Neurology. If researchers can't find a way to reduce the prevalence of the brain disease, the cost to care for all of these patients could top $1 trillion a year, experts say. Alzheimer's is a progressive brain disease that damages patients' memory and cognitive skills, ultimately leaving them unable to care for themselves.
January 7, 2013 |
Beta blockers, a venerable class of blood pressure drugs that has fallen from favor in recent years, may help protect the aging brain against changes linked to Alzheimer's disease and other forms of dementia that rob memory and mental function, new research indicates. In autopsies on the brains of 774 men after their deaths, scientists found that those who took beta blockers to help control hypertension had fewer of the brain lesions and less of the brain shrinkage seen in Alzheimer's than men who took other types of blood pressure medications and those who left the condition untreated.
January 3, 2013
Director Baz Luhrmann already tipped his hand in the trailer for his upcoming adaptation of "The Great Gatbsy. " Among the songs heard was the Jay-Z-led track "No Church in the Wild," his 2011 collaboration with Kanye West. The use married an examination of the empty, ostentatious wealth of the '20s with an examination of the empty, ostentatious wealth of today. This week, it came to light that "The Great Gatsby" could feature original Jay-Z works . The news was spread by the Bullitts, the musical designation for producer/musician Jeymes Samuel.
January 2, 2013 |
After sparking widespread comeback chatter last year with his album "The Bravest Man in the Universe," soul singer Bobby Womack has announced that he's experiencing early symptoms of Alzheimer's disease. "The doctor says, 'You have signs of Alzheimer's,' " Womack told the BBC's Gilles Peterson in an interview on the latter's Radio 6 program. "It's not bad yet, but it's gonna get worse. " Womack, 68, admitted that he's having trouble remembering things, including the name of Damon Albarn, who co-produced "The Bravest Man in the Universe" with XL Recordings chief Richard Russell.
December 13, 2012 |
YARUMAL, Colombia - The unusually high incidence of early-onset Alzheimer's disease in this isolated cattle town has thrust it to the forefront of global efforts to find a cure for the debilitating malady. Next spring, 100 residents of this region in northwestern Colombia who are known to carry a mutant gene linked to the disease will begin taking a therapeutic drug produced by the U.S. biotechnology firm Genentech. The five-year clinical trial, called the Alzheimer's Prevention Initiative, will cost $100 million.
November 27, 2012 |
A biological medication already widely used to treat plaque psoriasis may be able to slow the accumulation of amyloid plaques in the brain that are the hallmark of Alzheimer's disease, a new study has found. The same study found that in older mice with established Alzheimer's, this treatment approach, which suppresses the brain's immune reaction to beta amyloid, brought a marked improvement in cognitive function and may even halt or reverse early signs of Alzheimer's. The new study was published this week in the journal Nature Medicine.
September 5, 2012 |
As the National Football League kicks off a new season, a study appearing in a leading medical journal underscores the long-term costs of the game on those who play it. A study tracking 3,439 retired players with five or more seasons in the NFL found these athletes four times as likely as other men their age to die of Alzheimer's disease or amyotrophic lateral sclerosis, better known as Lou Gehrig's disease. Among the league's "speed players" - those who build up substantial speed before they make a tackle or are brought down by one - the odds of dying of those causes were even greater.